FibroBiologics, Inc. Common Stock
NASDAQ: FBLG0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter O'Heeron
- Employees
- 13
- Headquarters
- Houston, United States
- IPO year
- 2024
- Market cap
- $1.6M
- Website
- https://www.fibrobiologics.com
Loading FBLG…
Loading profile data…Frequently asked questions about FBLG
What does FibroBiologics, Inc. Common Stock (FBLG) do?
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. F...
Where does FBLG trade?
FibroBiologics, Inc. Common Stock (FBLG) trades on the NASDAQ Capital Market.
What sector is FBLG in?
FibroBiologics, Inc. Common Stock (FBLG) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of FibroBiologics, Inc. Common Stock?
Peter O'Heeron is the chief executive officer of FibroBiologics, Inc. Common Stock (FBLG).
Where is FibroBiologics, Inc. Common Stock headquartered?
FibroBiologics, Inc. Common Stock is headquartered in United States.
Does FBLG pay a dividend?
FibroBiologics, Inc. Common Stock (FBLG) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FBLG go public?
FibroBiologics, Inc. Common Stock (FBLG) completed its initial public offering in 2024.